Highlights Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.02 ^USD	-6.50%		+0.33%	-22.16%

Apr. 18	Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	CI
Mar. 12	Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 12	CI
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	Jan. 23	MT
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	Jan. 23	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Jan. 16	CI
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine	Dec. 06	CI
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology	Nov. 27	CI
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial	23-10-13	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-06	CI
Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial	23-08-07	CI
Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology	23-07-27	CI
Anixa Biosciences Reports Issuance of Canadian Patent for CAR-T Cancer Therapy Technology	23-07-11	MT
Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-14	CI
Anixa Biosciences, Inc. and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine	23-04-17	CI
Anixa Biosciences Receives Patent Allowance Notice For Breast Cancer Vaccine Technology	23-02-27	MT
Anixa Biosciences, Inc. Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology	23-02-27	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-01-04	CI
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine	22-12-08	CI
Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic	22-10-26	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-09-09	CI
Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial	22-08-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Highlights

Filters